[Influence of T-593 on the recurrence and relapse of cryocautery-induced gastric ulcer in rats: sequential observation with an endoscope and histological evaluation].
We investigated the influence of T-593, a novel anti-ulcer agent, on the recurrence and relapse of cryocautery-induced gastric ulcer in rats, in comparison with the action of famotidine and ranitidine. The drugs were administered from the 7th to the 119th day and then discontinued to the 190th day after induction of gastric ulcer. The healing, recurrence and relapse process of gastric ulcer was sequentially observed with an endoscope. In the control group, the reduction of ulcer index was observed until the 76th day after ulcer induction followed by aggravation, suggesting the recurrence and relapse occurred on cryocautery-induced gastric ulcer in rats. In the famotidine and ranitidine groups, the recurrence and relapse occurred after cessation of administration. The recurrence and/or relapse rate of T-593 was lower than those of other drugs. In the histological measurement, the grades of heterotopic regenerated gland and inflammatory cell infiltration of T-593 was lower than those of the control and other drugs in the ulcer area. From these results, it is concluded that T-593 induces ulcer healing with a lower recurrence and/or relapse rate of ulcers than other conventional H2-antagonists, and T-593 may thus be a useful anti-ulcer drug for clinical therapy.
Mori
Y
Y
Research Laboratories, Toyama Chemical Co., Japan.
Doi
Y
Y
Hashiba
K
K
Syouji
M
M
Mizuo
M
M
Marubuchi
S
S
Arai
H
H
D000818:Animals; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D002425:Cautery; D003452:Cryosurgery; D004724:Endoscopy; D015738:Famotidine / Q000627:therapeutic use; D006146:Guanidines / Q000627:therapeutic use*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D008297:Male; D011899:Ranitidine / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D012008:Recurrence; D013276:Stomach Ulcer / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D013450:Sulfones / Q000627:therapeutic use*
D000897:Anti-Ulcer Agents; D006146:Guanidines; D006635:Histamine H2 Antagonists; D013450:Sulfones; C088837:T 593; D015738:Famotidine; D011899:Ranitidine